BeOne Medicines AG (SHA:688235)
279.80
+3.45 (1.25%)
Oct 24, 2025, 3:00 PM CST
BeOne Medicines AG Revenue
BeOne Medicines AG had revenue of $1.32B USD in the quarter ending June 30, 2025, with 41.56% growth. This brings the company's revenue in the last twelve months to $4.56B, up 47.33% year-over-year. In the year 2024, BeOne Medicines AG had annual revenue of $3.81B with 54.96% growth.
Revenue (ttm)
$4.56B
Revenue Growth
+47.33%
P/S Ratio
7.46
Revenue / Employee
$414.73K
Employees
11,000
Market Cap
243.68B CNY
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.81B | 1.35B | 54.96% |
| Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
| Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
| Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
| Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Huadong Medicine | 42.62B |
| WuXi AppTec | 41.90B |
| Yunnan Baiyao Group Co.,Ltd | 40.84B |
| Shanghai Fosun Pharmaceutical (Group) | 40.12B |
| Shenzhen Mindray Bio-Medical Electronics | 32.94B |
| Jiangsu Hengrui Medicine | 30.15B |
| Zhejiang NHU Company | 22.87B |
| Aier Eye Hospital Group | 21.94B |
BeOne Medicines AG News
- 2 months ago - BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up - Benzinga
- 2 months ago - A Glimpse of BeiGene's Earnings Potential - Benzinga
- 2 months ago - BeiGene's Earnings: A Preview - Benzinga
- 2 months ago - BeiGene Q2 2025 Earnings Preview - Seeking Alpha
- 4 months ago - Glenmark Pharmaceuticals launches TEVIMBRA in India for advanced lung and esophageal cancer treatment - Business Upturn
- 4 months ago - Glenmark Pharmaceuticals to launch Zanubrutinib (BRUKINSA) in India after DCGI approval - Business Upturn
- 5 months ago - Cancer Stock Vaults 40% As Clinical Trial Shows 'Promise'; Sales Reach $1 Billion, Earnings To Triple - Investor's Business Daily
- 5 months ago - BeiGene gets EU backing for neck and head cancer treatment - Seeking Alpha